Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Exclusion Criteria

• •1. Other histological types of cervical cancer (eg, neuroendocrine carcinoma, small cell carcinoma, sarcoma, etc).
• •2. Evidence of distant metastases.
• •3. Have received total hysterectomy.
• •4. Subject with other active malignancies within 2 years prior enter the study.
• •5. Subject who cannot receive brachytherapy.
• •6. Active or prior documented autoimmune disease that may relapse.
• •7. History of interstitial lung disease or noninfectious pneumonitis.
• •8. Subject with the clinically significant cardio-cerebrovascular disease.
• •9. History of severe hypersensitivity reactions to other mAbs.
• •10. Prior allogeneic stem cell transplantation or organ transplantation.
• •11. Subjects who require systemic treatment with glucocorticoid (\>10 mg/day of prednisone or equivalent glucocorticoid) or other immunosuppressive agents within 14 days prior enter the study.
• •12. Receipt of live attenuated vaccines within 30 days prior to the first dose of the study drug.
• •13. Prior exposure to any experimental antitumor vaccines, or any agent targeting T-cell costimulation or immune checkpoint pathways (eg, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137 or anti-OX40 antibody, etc).
• •14. Any condition that, in the opinion of the Investigator, would interfere with the evaluation of the study drug or interpretation of subject safety or study results.